Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin for Prevention of ARDS
NCT03089957Completed
- Sponsor
- Peking University Third Hospital
- Start
- Feb 2017
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of ulinastatin in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: The incidence of ARDS at 3 years. Started Feb 2017; status: completed.
02
Drugs
ulinastatin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03089957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089957.